|
WO2020201038A1
|
|
Inhaled administration of lipocalin muteins
|
|
WO2020173897A1
|
|
Novel fusion proteins specific for cd137 and gpc3
|
|
WO2020043683A1
|
|
Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
|
|
AU2019315703A1
|
|
Novel fusion protein specific for CD137 and PD-L1
|
|
WO2020021061A1
|
|
Humanized anti-pd-1 antibodies and uses thereof
|
|
WO2018134279A1
|
|
Novel fusion polypeptides specific for lag-3 and pd-1
|
|
US2019345207A1
|
|
Lipocalin muteins with binding affinity for lag-3
|
|
WO2018087108A1
|
|
Proteins specific for cd137
|
|
CN107922470A
|
|
To 1 specific novel fusion polypeptide of LAG 3 and PD
|
|
CA2988831A1
|
|
Novel proteins specific for lag-3
|
|
KR20180002855A
|
|
Anticancer fusion polypeptide
|
|
KR20180008649A
|
|
The mutein of human lipocalin 2 with affinity for glypicane-3 (GPC3)
|
|
AU2016258977A1
|
|
Anti-cancer fusion polypeptide
|
|
EP3292137A1
|
|
Proteins specific for cd137
|
|
AU2016221816A1
|
|
Novel proteins specific for pyoverdine and pyochelin
|
|
CA2973640A1
|
|
Novel proteins specific for angiogenesis
|
|
KR20170004011A
|
|
Novel specific-binding polypeptides and uses thereof
|
|
CN109432402A
|
|
Method by inhibiting IL-4 and/or IL-13 to prevent in conjunction with its respective receptor or treat certain obstacles
|
|
EP2646552A1
|
|
Muteins of human lipocalin 2 with affinity for ctla-4
|
